Welcome to our dedicated page for Oreilly Automotive SEC filings (Ticker: ORLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
O鈥橰eilly Automotive鈥檚 success hinges on relentless parts availability and razor-thin inventory margins鈥攆acts buried deep inside every 10-K and 10-Q. If you have ever asked, 鈥淲here can I find O鈥橰eilly Automotive鈥檚 quarterly earnings report 10-Q filing?鈥� or struggled to locate Form 4 insider trades before a parts-shortage headline, this page is built for you.
Stock Titan鈥檚 AI reads each disclosure the moment it hits EDGAR and delivers plain-English answers. From O鈥橰eilly Automotive annual report 10-K simplified breakdowns of same-store sales to line-by-line O鈥橰eilly Automotive proxy statement executive compensation comparisons, our summaries spotlight what drives aftermarket revenue. AG真人官方-time alerts capture O鈥橰eilly Automotive Form 4 insider transactions real-time, helping you track executive stock moves the minute they鈥檙e filed.
Looking for specifics? Our platform links every filing type to the questions professionals ask:
- Form 4 鈥� 鈥淥鈥橰eilly Automotive insider trading Form 4 transactions鈥� and 鈥淥鈥橰eilly Automotive executive stock transactions Form 4鈥� surfaced instantly.
- 10-Q 鈥� Quick-read AI tables show inventory turns, margins, and unit growth with O鈥橰eilly Automotive earnings report filing analysis.
- 8-K 鈥� O鈥橰eilly Automotive 8-K material events explained so you see supply-chain disruptions or leadership changes without parsing legal prose.
- 10-K 鈥� Multi-year trends, distribution center investments, and SKU counts under 鈥渦nderstanding O鈥橰eilly Automotive SEC documents with AI.鈥�
Whether you monitor O鈥橰eilly Automotive SEC filings explained simply for macro insights or need a fast signal before earnings, our comprehensive, AI-powered coverage saves hours and sharpens decisions.
ALT5 Sigma Corporation (NASDAQ: ALTS) filed an 8-K announcing the May 9 2025 acquisition of 鈥淢swipe,鈥� a Canada-based provider of multi-currency, fiat- and crypto-enabled payment card solutions available on Visa and Mastercard networks.
- Strategic rationale: Mswipe鈥檚 B2B platform extends ALT5鈥檚 existing digital-asset settlement offering by adding globally usable physical & virtual cards, real-time FX/crypto conversion and robust compliance.
- Consideration: (i) 1 million restricted ALTS shares valued at $6.10 each (~$6.1 M); (ii) 500 k four-year warrants exercisable at $5.50; (iii) $4.8 M in shares of spin-off Alyea Therapeutics; (iv) two 14-month promissory notes totalling ~$1 M at 3.99% interest; and (v) assumption/reset of an existing $5.1 M target-level note.
- Contingent payout: Sellers may receive a one-time earn-out of up to $20 M (cash or stock) if the operating subsidiaries reach 鈮�$15 M annualised or actual revenue.
- Audited FY25/FY24 Mswipe financials (Ex. 99.1) and unaudited pro-forma combined statements (Ex. 99.2) were filed; a press release (Ex. 99.3) was issued on May 13 2025.
No immediate revenue or EPS guidance was provided. The transaction is expected to close seamlessly as ALT5 integrates card issuance, aiming to bridge digital assets with traditional payment rails.
Form 4 filed 07/01/2025: Atlassian Corporation (TEAM) Co-Founder, CEO, Director and 10% owner Michael Cannon-Brookes converted 490,560 Class B shares into Class A shares (Transaction Code C). The Class B shares were held by CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust. The conversion was executed in connection with sales to be effected under a Rule 10b5-1 trading plan adopted on 02/20/2025.
Following the transaction, Cannon-Brookes鈥� reported holdings are:
- Class A common stock: 490,560 shares (indirect)
- Class B common stock (convertible one-for-one with no expiration): 48,024,933 shares (indirect)
No price was paid for the conversion (exercise price $0.00). The filing signals preparation for future open-market sales while complying with Section 16 reporting obligations and the updated Rule 10b5-1 affirmative-defense conditions.